Equity Overview
Price & Market Data
Price: $16.36
Daily Change: -$0.11 / 0.67%
Daily Range: $16.13 - $16.57
Market Cap: $1,139,782,016
Daily Volume: 10,015
Performance Metrics
1 Week: 6.93%
1 Month: -8.71%
3 Months: 2.83%
6 Months: 33.88%
1 Year: 82.79%
YTD: -7.41%
Details
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.